Allogene Therapeutics, Inc. (ALLO) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ALLO's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross."A golden cross is a technical chart pattern that can signify a potential bullish breakout. It's formed from a crossover involving a security's short-term moving average breaking above a longer-term moving average, with the most common moving avera ...

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report fourth quarter and full year 2023 financial results and provide a business update on March 14, 2024, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/ ...

公司财务报表重新核算 - Allogene Therapeutics宣布将重新核算2019年至2022年的财务报表，主要是由于在2020年12月成立亚洲Allogene Overland Biopharm合资企业所导致的非现金会计调整[1] - 重新核算的财务报表不会对公司的现金、现金等价物和可市场化投资、现金运营或业务运营产生影响，公司仍有足够的财务资源支持运营至2026年[2] - 公司计划在2024年3月14日或之前提交修订后的财务报表，并报告2023年第四季度和全年财务业绩，以确保信息的准确性和透明度[3]

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in three upcoming investor conferences in January and February. B. Riley Oncology ConferenceThursday, January 18, 202412:30PM PT/3:30PM ET Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceWednesday, February ...

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in three upcoming investor conferences in January and February. B. Riley Oncology ConferenceThursday, January 18, 202412:30PM PT/3:30PM ET Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceWednesday, February ...

医疗 - 生物医学和遗传学领域 - Allogene Therapeutics, Inc. (ALLO) 是医疗 - 生物医学和遗传学领域的一个有趣选择[1] - 医疗 - 生物医学和遗传学领域目前处于良好位置，Zacks Industry Rank 为 61[2] 公司表现 - Allogene 近期看起来也不错，过去一个月内，盈利预期有所提升[3] - 目前公司的 Zacks Rank 为 3 (Hold)，也是一个积极信号[4]

Partnership Will Utilize Foresight's Ultra-Sensitive MRD Technology to Identify Patients for Enrollment in Allogene's ALPHA3 Trial SAN FRANCISCO and BOULDER, Colo., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products, and Foresight Diagnostics (Foresight), the leader in the development of ultra-sensitive liquid biopsy circulating tumor DNA (ctDNA) detection today announced a st ...

Four Core Programs Leverage Unique Attributes in Product Development and Trial Design to Demonstrate the Unmatched Potential of an Allogeneic CAR T Large B-Cell Lymphoma (LBCL): Groundbreaking ALPHA3 Trial has Potential to Leapfrog Other CAR Ts and Embed Cemacabtagene Ansegedleucel (Cema-Cel, Previously ALLO-501A) in First Line (1L) Treatment in Community Cancer Centers Where Most Newly Diagnosed Patients Seek CareChronic Lymphocytic Leukemia (CLL): New ALPHA2 Cohort Designed to Address a Limitation of Auto ...

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will host a conference call to preview its 2024 Platform Vision focused on redefining the future of CAR T by leveraging the unique attributes of allogeneic CAR T products. The 2024 Platform Vision conference call will be hosted on Thursday, January 4, 2024, at 2 ...

财务数据和关键指标变化 - 公司2023年第三季度研发费用为4600万美元,其中包括670万美元的非现金股票激励费用 [32] - 公司2023年第三季度一般及行政费用为1700万美元,其中包括860万美元的非现金股票激励费用 [32] - 公司2023年第三季度净亏损为6130万美元,每股0.37美元,包括1540万美元的非现金股票激励费用 [32] - 公司预计2023年全年现金、现金等价物和投资减少约2.3亿美元,2023年全年GAAP经营费用约3.4亿美元,其中包括约8000万美元的非现金股票激励费用 [33] 各条业务线数据和关键指标变化 - 公司正在推进潜在关键性试验ALPHA2,已在美国、加拿大、欧洲和澳大利亚开放入组 [46] - 公司正在推进EXPAND试验,目前已在美国和欧洲开放入组,未来几周内还将在澳大利亚开放 [69] - 公司正在推进TRAVERSE试验,目前入组进展顺利,受试者和研究者的热情持续高涨 [57] 各个市场数据和关键指标变化 - 公司正在积极拓展ALPHA2和EXPAND试验的地理覆盖范围,以增加患者入组来源,包括美国以外的国家和地区 [46][69] - 公司认为在一些国家和地区,由于自体CAR-T疗法的可及性和使用较低,这些地区的患者入组将更加顺利 [77] 公司战略和发展方向及行业竞争 - 公司认为异基因CAR-T疗法是实现CAR-T疗法广泛可及的关键 [12][13] - 公司正在开发新一代的"隐身"和"匕首"技术,旨在提高异基因CAR-T细胞的植入、扩增和持久性 [23] - 公司正在制定将CAR-T疗法推广到更早线治疗的策略,以应对自体CAR-T疗法向更早线推进的趋势 [24][25] 管理层对经营环境和未来前景的评论 - 公司认为CAR-T疗法正处于第四波创新浪潮的开端,异基因CAR-T是实现这一潜力的关键 [12][13] - 公司对TRAVERSE试验的进展和结果充满信心,希望能为晚期或转移性肾细胞癌患者提供另一治疗选择 [26] - 公司认为,随着自体CAR-T疗法向更早线治疗推进,公司需要制定相应策略以应对这一变化 [24][25] 问答环节重要的提问和回答 问题1 **Michael Yee 提问** 询问ALPHA2试验的地理覆盖和患者入组情况,以及TRAVERSE试验数据更新时间 [37] **David Chang 回答** 公司正在多个国家和地区开展ALPHA2和EXPAND试验,预计将有来自美国和海外的患者入组。TRAVERSE试验数据更新计划在2024年初发布 [46][49] 问题2 **Tyler Van Baron 提问** 询问EXPAND试验的入组情况,以及公司是否会在ALPHA2数据出来时向FDA提交EXPAND的数据 [60] **Zachary Roberts 回答** EXPAND试验采用随机分组设计,公司预计不会出现入组差异。公司计划在ALPHA2数据成熟时,同时向FDA提交EXPAND的数据 [62][63] 问题3 **Brian Cheng 提问** 询问公司进入ALLO-316 CD70项目关键性试验的标准是什么 [65] **David Chang 回答** 公司希望ALLO-316在CD70阳性患者中能达到约30%的反应率,这将是一个有意义的改善,公司认为这可能成为进入关键性试验的标准 [66]